Collegium Pharmaceutical, Inc. (COLL) Fundamentals — Income, Balance Sheet & Cash Flow | MarketCI

Collegium Pharmaceutical, Inc. (COLL) Fundamentals — Income, Balance Sheet & Cash Flow | MarketCI | MarketCI

COLL

Market Closed

Collegium Pharmaceutical, Inc.

NASDAQHealthcare Drug Manufacturers - Specialty & Generic

423 employees

CEO: Vikram Karnani

Founded: 2015

$35.20

+$0.00(+NaN%)

Market Cap

1.14B

Beta

0.73

52W Range

N/A

Dividend Yield

0.00%

Overview Forecasts Fundamental Market Sentiment Valuation Ownership

Financial Statements

Comprehensive breakdown of financial statements and performance metrics

Gross Margin

59.3%

22.8%

CAGR: 32.4%

Profit after direct costs

Operating Margin

24.0%

10.1%

CAGR: 80.5%

Core business profitability

Net Margin

8.1%

-9.1%

CAGR: -3.2%

Bottom line profitability

Revenue Growth

23.6%

YoY

CAGR: 29.6%

Top line growth rate

Revenue Flow Analysis

Visual flow showing how COLL allocates revenue across expenses and profit

Fiscal Year 2025

Revenue Distribution

Flow of revenue through cost categories to net income

Gross Margin

59.3%

$463.26M

Operating Margin

24.0%

$187.08M

Net Margin

8.1%

$62.87M

Detailed Income Statement

Complete profit and loss breakdown with margin analysis and historical comparison

Item	2021	2022	2023	2024	2025	YoY Change
Total Revenue	276.87M	463.93M	566.77M	631.45M	780.57M	23.6%
Cost of Revenue	(126.25M)	(254.44M)	(240.60M)	(254.10M)	(317.31M)	24.9%
Gross Profit	150.62M	209.49M	326.17M	377.34M	463.26M	22.8%
Operating Expenses
Research & Development	(9.45M)	(3.98M)	—	—	—	—
Selling, General & Administrative	(118.96M)	(172.19M)	(159.21M)	(182.98M)	(276.17M)	50.9%
Depreciation & Amortization	(68.92M)	(138.94M)	(149.26M)	(169.16M)	(226.07M)	33.6%
Operating Income (EBIT)	17.63M	33.32M	166.96M	169.90M	187.08M	10.1%
Non-Operating Items
Interest Income	12.00K	1.05M	15.62M	13.98M	11.29M	-19.2%
Interest Expense	(21.01M)	(63.21M)	(83.34M)	(73.97M)	(82.31M)	11.3%
Other Income/Expenses (Net)	-21.00M	-62.17M	-91.23M	-71.33M	-94.47M	32.4%
Income Before Tax	-3.37M	-28.85M	75.73M	98.57M	92.62M	-6.0%
Income Tax Expense	(74.89M)	(3.85M)	(27.58M)	(29.38M)	(29.75M)	1.3%
Net Income	71.52M	-25.00M	48.16M	69.19M	62.87M	-9.1%
Per Share Metrics
Earnings Per Share (Basic)	$2	$-1	$2	$2	$2	-7.5%
Weighted Avg Shares Outstanding	34.94M	33.83M	33.74M	32.27M	31.71M	-1.8%
Weighted Avg Shares Outstanding (Diluted)	41.05M	33.83M	41.79M	40.42M	39.70M	-1.8%
EBITDA	86.56M	173.31M	308.33M	341.70M	401.00M	17.4%

Explore COLL

Overview

Key metrics and AI-powered insights

Forecast

Price targets and earnings estimates

Fundamentals

Income, balance sheet and cash flow

Valuation

P/E, DCF and valuation multiples

Ownership

Institutional and insider holdings

Sentiment

Analyst ratings and news sentiment

COLL in the Healthcare

Small Cap

Healthcare

Browse sector stocks →

Drug Manufacturers - Specialty & Generic

Browse industry stocks →